Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.
More news for Friday, April 8
By
Kimberly Bonvissuto
Apr 08, 2022
CBRE Seniors Housing & Care Investor Survey identifies industry trends … Senior housing staffing shortages move from severe to moderate: NIC … CMS finalizes Medicare coverage policy for Alzheimer’s...
Few older adults knowledgeable about aducanumab for Alzheimer’s disease
Feb 25, 2022
Less than one-quarter of older adults report they would want to take aducanumab (Aduhelm).
U.S. senate narrowly confirms Califf to head FDA
Feb 15, 2022
Califf briefly served as FDA commissioner toward the end of President Barack Obama’s administration.
Should residents’ access to Alzheimer’s drug be restricted?
By
Lois A. Bowers
Jan 18, 2022
You have until Feb. 10 to share your comments with CMS about its recent proposal related to Alzheimer’s drug aducanumab (Aduhelm).
Senate committee backs Califf nomination to head FDA
Jan 14, 2022
Among those who voted against Califf’s nomination were Democrats who expressed concerns about his links to pharmaceutical companies.
Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
Health habits’ connection to dementia in the spotlight as new year begins
By
Lois A. Bowers
Jan 04, 2022
An update to the National Plan to Address Alzheimer’s Disease, as well as news of potential treatments and a finding that “astonished” researchers add up to promising news to start the new...
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
ARIA described from clinical trials of aducanumab for Alzheimer’s disease
Dec 10, 2021
Amyloid-related imaging abnormalities-edema seen on brain MRI was the most common adverse event in participants receiving high-dose aducanumab (Aduhelm).